Business Wire

AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism

5.7.2022 18:00:00 EEST | Business Wire | Press release

Share

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating that ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury (AKI) has been published in the journal, Frontiers in Medicine-Nephrology. The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI. The publication is available now online at https://www.frontiersin.org/articles/10.3389/fmed.2022.931293/abstract.

This study provides further insight into the mechanism of action of ilofotase alfa, showing that adenosine receptor signaling plays a role in the activity of the drug by restoring homeostasis through conversion of extracellular ATP into adenosine activating anti-inflammatory adenosine receptor signaling in common AKI animal models. The 1000 U/Kg dose tested in this study is, comparable to the dose currently being tested in the global phase III pivotal study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury (SA-AKI).

“We are very encouraged by the findings of this study, as these data further validate the role of ilofotase alfa in protecting the kidney during episodes of acute kidney injury,” said Maarten Kraan, MD, PhD, Chief Medical Officer of AM-Pharma. “The results reported by the esteemed authors of this publication show that augmentation of adenosine signaling is a key component of the mechanism of action of ilofotase alfa in rodent ischemia-reperfusion induced AKI and provide additional evidence of the potential of ilofotase alfa as a treatment option for AKI.”

About Ilofotase Alfa

Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active. The recombinant enzyme displays exquisite activity towards dephosphorylating and detoxifying damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), ATP, ADP and other extracellular substrates that drive acute inflammation, coagulation and microvascular ischemia found in kidney following sepsis or ischemia-induced damage. Research has shown that ATP dephosphorylation has a double effect in protecting against kidney injury. When the pro-inflammatory ATP is dephosphorylated, the resulting adenosine further reduces inflammation through the activation of the immunosuppressive adenosine A2a receptor pathway.

About AM-Pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors:
Argot Partners
+1 212.600.1902
AMPharma@argotpartners.com

Media:
Trophic Communications
Gretchen Schweitzer
+49.89.238.877.30
am-pharma@trophic.eu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Global Deepens Private Client Tax Capabilities with KTA Tax15.10.2026 16:30:00 EEST | Press release

Andersen Global broadens its private client tax capabilities through a Collaboration Agreement with KTA Tax, a Dublin-based tax practice that has advised individuals and families for nearly three decades. KTA Tax has advised private clients and their families since 1997, combining the personal approach of a boutique practice with deep technical knowledge of Irish taxation. Its services span transaction and tax planning, estate planning, investments and pensions, cross-border matters, Revenue interventions, employment tax, and annual personal tax compliance. “We have remained focused on one thing: providing clear, thoughtful tax advice that reflects the individual circumstances of our clients and their families,” said Lisa Cantillon, CEO of KTA Tax. “Collaborating with Andersen Global is an important step for KTA Tax, giving us an opportunity to build on that foundation while extending the resources available to the clients we serve.” “Private client work demands an understanding of mor

Sysco Awards Partner of the Year Award to Grid Dynamics15.10.2026 16:15:00 EEST | Press release

Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”) today announced that Sysco, the global foodservice distribution leader, has named the company its Partner of the Year. The recognition honors Grid Dynamics’ approach and expertise in bringing AI into Sysco’s technology and business operations. Sysco is the global leader in foodservice distribution, generating $84.6 billion in sales for its fiscal year ended June 27, 2026, and serving approximately 670,000 customer locations across 10 countries. The partnership began in 2024 with Grid Dynamics teams working alongside Sysco across product search and discovery, digital commerce, and AI-first software development. Grid Dynamics delivered a range of projects that made everyday work easier for Sysco's associates, enhanced the customer experience, and generated measurable business value. “What makes this partnership work is how closely our teams operate together,” said Ragnarok Rocha, Vice President, Digital Commerce and Customer S

The Outcome Economy at Work – New Research From Vertage15.10.2026 16:01:00 EEST | Press release

Three in four enterprises (74%) define significant work around outcomes, but only 15% are ready to deliver it consistently, according to new global research from HR tech leader Vertage. These ‘outcome-ready’ enterprises report higher customer satisfaction (91% vs. 67%), stronger delivery of strategic goals (86% vs. 65%) and faster conversion of opportunities into value (85% vs. 64%). They also have a cultural edge: 69% of their employees understand their contribution and can adapt how they work, compared with 34% elsewhere. "AI adoption no longer separates strong businesses from the rest. Outcome readiness does," said Edzard Overbeek, Group CEO of Vertage. "The strongest businesses organize people, partners and AI around a clear result, and they keep human judgment at the center." The study, The Outcome Economy at Work, draws on 800 enterprise decision-makers and 1,200 workers across six markets, plus in-depth interviews with senior leaders. Its central finding is clear: outcome-based

Introducing Ledger Atom™—Everything You Value, Finally Secure15.10.2026 15:45:00 EEST | Press release

Ledger™, the global leader in secure infrastructure for digital ownership, today unveiled Ledger Atom™, a security and privacy device that runs your everyday apps, purpose-built to help protect your money, your AI agent approvals, and your privacy. The innovative architecture of Ledger Atom, leveraging Android™ open source alongside Ledger OS™, Ledger’s proprietary security-first operating system running on a secure element chip, allows you to approve sensitive actions in a secure environment while using all your everyday apps on a single device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015445765/en/ Ledger has launched Ledger Atom, a security and privacy device that runs your everyday apps, purpose-built to help protect your money, your AI agent approvals, and your privacy. Your phone is not secure, and threats targeting it are escalating; mobile zero-days nearly doubled year over year in 2025, and commercial spywa

Meet Yuvo - The All-In-One Platform Helping Travel Brands Optimize Every Stage of Their Customer's Journey15.10.2026 15:36:00 EEST | Press release

Yuvo data shows that flight disruption hit more than 913 million passengers in 2025, and travellers are now buying travel protection at six times the pre-pandemic rate. Yet for most travel brands, a delayed flight still means support calls, refunds and lost customers. Yuvo turns those moments, and every other step of the trip, into revenue and loyalty. Most travel brands earn from their customers only once: when they book. Yuvo changes that. It helps partners earn across the whole journey, with no technology to build and full control of the customer relationship. Yuvo works with some of the biggest names in travel, turning the customer relationships they already have into an ongoing revenue stream while keeping them fully in control. Built by a team of seasoned travel tech experts, the platform has already helped more than 26 million travelers through its services, improving customer experience and building loyalty worldwide. Yuvo’s Services - adding value at every stage of the journey

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye